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Abstract 
Background: An increasing number of reports have documented the emergence of daptomycin‑nonsusceptible 
Enterococcus in patients during daptomycin therapy. Even though several mechanisms for daptomycin‑nonsuscepti‑
bility have been suggested, the potential genetic mutations which might contribute to the daptomycin‑nonsuscepti‑
bility are not fully understood.
Case presentation: We isolated a vancomycin‑susceptible, daptomycin nonsusceptible Enterococcus faecium strain 
from a patient with acute lymphocytic leukemia who received high‑dose daptomycin therapy for E. faecium endocar‑
ditis. Whole‑genome sequencing analysis revealed mutations within genes encoding DNA repair proteins MutL and 
RecJ of the daptomycin‑nonsusceptible Enterococcus strain which might have facilitated its emergence.
Conclusions: We identified the mutations of DNA mismatch repair genes in a clinical isolate of daptomycin non‑
susceptible E. faecium which emerged in spite of high‑dose daptomycin therapy. The finding implicates the possible 
association of DNA repair mechanism and daptomycin resistance. Careful monitoring is necessary to avoid the emer‑
gence of daptomycin non‑susceptible isolates of E. faecium and particularly in cases of long‑term daptomycin use or 
in immunocompromised patients.
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Background
Daptomycin (DAP) is a lipopeptide antibiotic that exhib-
its potent activity against gram-positive bacteria, includ-
ing vancomycin-resistant enterococci (VRE); however, 
an increasing number of reports have documented the 
emergence of daptomycin-nonsusceptible Enterococ-
cus (DNSE) in patients during DAP therapy [1–4]. Even 
though several mechanisms for daptomycin-non-suscep-
tibility have been suggested [5, 6], the potential genetic 
mutations which might contribute to the daptomycin-
nonsusceptibility are not fully understood. In this report, 
we describe vancomycin-susceptible, daptomycin non-
susceptible Enterococcus (DNSE) faecium strain from a 
patient with acute lymphocytic leukemia who received 
high-dose DAP therapy. The whole-genome sequencing 
analysis revealed mutations within genes encoding DNA 
repair proteins MutL and RecJ.
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Case presentation
A 32-year-old Japanese man with Philadelphia chromo-
some-positive acute lymphocytic leukemia (ALL) devel-
oped fever during chemotherapy with dasatinib and 
doxorubicin with dexamethasone for treatment of ALL 
relapse approximately 3 months after hematopoietic stem 
cell transplantation. The patient’s blood culture was posi-
tive for E. faecium, and, as he was allergic to vancomycin, 
teicoplanin therapy was initiated. Dasatinib and doxo-
rubicin were discontinued immediately. The minimum 
inhibitory concentrations (MICs) of various antibiot-
ics are listed in Table  1 (EFM01). Although the MIC of 
teicoplanin for the E. faecium strain was ≤2 mcg/ml, and 
the patient’s serum teicoplanin trough was maintained 
between 20 and 22 mcg/ml, E. faecium was consistently 
detected in his blood cultures for more than 3 weeks. In 
addition, the patient was neutropenic during this period, 
with neutrophil counts between 300 and 830 neutrophils/
ml.
After consulting the infectious disease service for rec-
ommendations on treating the persistent E. faecium 
infection, the treatment plan was modified to include 
gentamicin therapy (1.3  mg/kg every 12  h), and imag-
ing studies and an endoscopy were ordered to identify 
the nidus of the persistent E. faecium bacteremia. A 
transthoracic echocardiogram subsequently revealed a 
vegetation, measuring a few millimeters in size, on the 
patient’s aortic valve. Meanwhile, chest and abdominal 
CT scans detected a thickened colon wall, but no other 
lesions, and a PET scan failed to identify a potential 
source of the infection. A colonoscopy, however, revealed 
erosion throughout the colonic mucosa, which was con-
sidered consistent with graft versus host disease and was 
considered the likely entry site of E. faecium into the 
bloodstream.
As the E. faecium bacteremia persisted for 2  weeks 
after initiation of the gentamicin therapy (gentamicin 
MIC was 16  mcg/ml) in combination with teicopla-
nin, the patient was switched to 10 mg kg−1 day−1 DAP 
[DAP; Etests indicated that the MIC of DAP for the E. 
faecium strain was 4  mcg/ml as in Table  1 (EFM01)]. 
After initiation of DAP therapy, the patient’s fever sub-
sided and subsequent blood cultures were negative. As a 
result, after receiving the initial dose of DAP for 18 days, 
the dose was reduced to 6 mg kg−1 day−1. However, 1 day 
after reducing the dose, the patient developed fever again 
and his blood culture tested positive for E. faecium (DAP 
MIC, per Etest: 256  mcg/ml). The MICs for other anti-
biotics are listed in Table 1 (EFM02). DAP was therefore 
discontinued, and treatment with intravenous linezolid 
(600 mg every 12 h) was initiated. While blood cultures 
were negative after 2 days of linezolid therapy, the patient 
unfortunately passed away owing to exacerbation of the 
ALL at 26 days after initiation of treatment with linezolid.
Molecular analysis of the daptomycin-susceptible 
(EFM01; isolated prior to the initiation of DAP) and 
daptomycin non-susceptible E. faecium (DNSE; EFM02) 
isolates was conducted in the Pathogenic Microbe Labo-
ratory at the Research Institute of the National Center for 
Global Health and Medicine in Tokyo, Japan. The strains 
were cultured in brain heart infusion (BHI) broth over-
night, and genomic DNA was purified using a DNeasy 
Blood & Tissue kit (Qiagen, Venlo, Netherlands). The 
genomes of the two isolates were then subjected to 
MiSeq sequencing using Nextera XT library kits (Illu-
mina, Inc., San Diego, CA, USA), according to the manu-
facturer’s instructions. Approximately 1 million pair-end 
reads (301 base pairs [bp] × 2) were obtained from each 
genome and analyzed using CLC Genomics Workbench 
software (CLC bio, Aarhus, Denmark). The reads from 
each isolate were trimmed by screening for base quality 
(quality score limit =  0.05; reads that contained greater 
than two ambiguous nucleotides or that were less than 
15 bp in length were removed), and then used to gener-
ate de novo genome assemblies, respectively. Meanwhile, 
the contigs were used as the reference genome. The reads 
from each isolate were then mapped to the reference 
genome, and variants were detected using CLC Genom-
ics Workbench program that is based on the algorithm 
developed by Smith and Waterman (1981) [7]. For these 
analyses, the following detection parameters were used: 
95  % coverage and more than 10 overlapping reads. 
Table 1 Susceptibility profile of resistance genes of Enterococcus faecium isolates
PCG penicillin G, ABPC ampicillin, MINO minocycline, VCM vancomycin, TEIC teicoplanin, LVFX levofloxacin, LZD linezolid, DAP daptomycin, S susceptible, I intermediate, 
R resistant
a MIC interpretive criteria, per the clinical and laboratory standards institute (CLSI; M100–S24) [20]
Isolate Resistance genes Minimum inhibitory concentrations (MIC) (μg/ml)/Interpretive criteriaa
Aac(6′)-Ii Ant(6)-Ia Aph(3′)-III ErmB MsrC TetM PCG ABPC EM MINO VCM TEIC LVFX LZD DAP
EFM01 + + + + + + ≥16/R ≥16/R ≥8/R 8/I 1/S ≤2/S ≥8/R ≤2/S 4/S
EFM02 + + + + + + ≥16/R ≥16/R ≥8/R 8/I 1/S ≤2/S ≥8/R ≤2/S 256/–
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Because the settings used can yield false-positive vari-
ants, each putative variant was manually confirmed by 
examining the mapping results. The resulting sequencing 
data were registered with the DNA Data Bank of JAPAN 
(DDBJ, accession number DRA03513). Furthermore, to 
annotate variants that were unique to the strains exam-
ined in this study, the genome sequence of E. faecium 
Aus0085 was used as a Ref. [8].
The MICs of multiple antimicrobials for the two E. 
faecium isolates, as well as the antimicrobial resist-
ance genes encoded by these organisms, as identified 
by analysis of contigs using the ResFinder program [4], 
are summarized in Table  1. Comparison of the EFM01 
and EFM02 genomes at SNP level based on whole 
genome sequencing indicated that EFM02 was derived 
from EFM01. While EFM02 contained 40 variants that 
were not present in EFM01, each of the variants identi-
fied in EFM01 were present in EFM02. The variants that 
resulted in amino acid substitutions within the genome 
of EFM02 compared to that of EFM01 are summarized 
in Table 2.
Notably, by comparing the genomes of the two E. fae-
cium isolates, we detected mutations that were present 
in the genes encoding the DNA repair proteins MutL 
(mutL) and RecJ (recJ) of the DNSE strain, but not the 
DAP-susceptible parental strain. We, therefore, inves-
tigated whether the disruption of these genes affected 
the frequency of mutations in the E. faecium genome. 
For these analyses, each strain was cultured overnight in 
2 ml of BHI broth. The following day, 2 μL of the result-
ing cultures was used to inoculate 2  ml of BHI broth, 
respectively. The cultures were again incubated over-
night, diluted in fresh broth, and plated on BHI agar. Sub-
sequently, 11 distinct colonies of each strain (EFM01 and 
EFM02) were harvested, and whole-genome sequencing 
of these isolates was conducted, as described above. The 
reads obtained from each isolate were mapped to the 
respective parental genome and analyzed for the pres-
ence of newly acquired variants. Because the settings 
used can yield false positive variants, any variants that 
were also present in the parental genome were excluded, 
and each putative variant was manually confirmed by 
examining the mapping results.
There was only one newly acquired variant identi-
fied after analysis of the genomes of the 11 daptomycin-
susceptible E. faecium (EFM01) after the bacteria had 
undergone 9.2 generations. Conversely, analysis of the 
genomes of the 11 DNSE (EFM02) isolates detected 49 
variants after the bacteria had undergone 9.4 generations. 
These findings indicate that the observed alterations to 
the mutL and recJ genes may have resulted in a signifi-
cant increase in the frequency of mutations in the EFM02 
genome.
Discussion
In this report, we characterized a strain of E. faecium with 
high level of DAP resistance (MIC =  256 mcg/ml) that 
was isolated from a patient with ALL following 20 days of 
exposure to high-dose DAP (10 mg kg−1 day−1) for treat-
ment of E. faecium endocarditis. Subsequent genomic 
analyses indicated that this DNSE strain contained muta-
tions within the known DNA repair genes mutL and recJ, 
which may have contributed to the acquisition of DAP 
resistance. Although dasatinib was reported to have 
effect on DNA repair pathways in human cancer cell 
lines [9], the association of DNA repair gene mutations 
of bacterial isolates with dasatinib or doxorubicin has not 
been reported to the best of our knowledge. In this case, 
dasatinib and doxorubicin were discontinued at the time 
of the first episode of E. faecium bacteremia, and thus, 
the patient was not receiving these drugs during DNSE 
emergence.
In a previous study of 42 cases of DNSE infection, 
which included five cases due to vancomycin-suscepti-
ble DNSE, only two VRE strains (4.2  %) exhibited DAP 
MICs ≥128 mcg/ml [10]. Meanwhile, the most common 
underlying disease associated with DNSE infection was 
hematologic malignancy (35  %), which was also present 
in the current case [10]. Indeed, immunosuppression and 
prior exposure to cephalosporins and metronidazole are 
considered independent predictors of infections caused 
by DNSE [11]. While in vitro analyses indicated that the 
acquisition of DAP resistance requires at least 6 days of 
exposure to DAP [6], the median duration of DAP expo-
sure in previous case series of DNSE was 16–19 days [12, 
13], which is similar to the duration of DAP treatment in 
the current case (20 days).
In recent reports of DNSE that developed dur-
ing DAP therapy, patients received 6  mg/kg DAP 
[1–3, 14]. Meanwhile, separate studies demonstrated 
that ≥8 mg kg−1 day−1 of DAP resulted in improved clin-
ical outcomes in cases of VRE blood stream infections, 
but that an even higher dose of DAP (≥10 mg kg−1 day−1) 
might be required to prevent the development of DAP 
resistance [6, 15]. In the current case, however, DNSE 
survived high-dose DAP therapy (10  mg  kg−1  day−1). 
While recent studies suggest that increases in DAP MICs 
are associated with decreases in the MIC of beta-lactams 
[16], further investigation is required to assess whether 
the inclusion of beta-lactams such as ampicillin might 
help prevent the development of DNSE. Furthermore, 
a recent meta-analysis indicated that linezolid is more 
effective than is DAP for treatment of VRE bacteremia 
and that linezolid was associated with decreased rates of 
mortality [17]. However, the side effects associated with 
this antimicrobial, particularly adverse hematologic reac-
tions, hinder its long-term use.
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The mechanisms underlying DAP non-susceptibil-
ity in enterococci are not fully understood, but recent 
reports suggest the involvement of the cardiolipin syn-
thase enzyme as well as several genetic pathways, includ-
ing those associated with cell membrane phospholipid 
metabolism and the response of the bacterial cell-enve-
lope to antibiotics [5]. We did not identify mutations that 
have been previously determined to confer daptomycin 
non-susceptibility in E. faecium, such as liaFSR, yycF-
GHIJ, cardiolipin synthetase, or ezrA [5]. However, we 
identified multiple amino acid changes predicting gene 
products which were reported previously in daptomycin 
non-susceptibile E. faecium isolates by whole-genome 
analyses, as shown in Table 2. In addition, we identified 
mutations within the DNA repair genes mutL and recJ 
that were unique to the DNSE strain and demonstrated 
that these mutations might have facilitated the emer-
gence of spontaneous mutations during subculturing. We 
propose that this increased frequency of mutation might 
have led to the observed emergence of the DNSE phe-
notype. Contrary to this hypothesis, in a previous study, 
Willems et al. failed to detect demonstrable hypermuta-
tor phenotypes in oxazolidinone-resistant or -susceptible 
E. faecium isolates with mutations in the mutLS locus 
[18]. However, it is possible that the distinct phenotypes 
associated with alterations in the mutL gene could be due 
to differences in the genetic position of the individual 
mutL mutations [18]. Meanwhile, the recJ gene encodes a 
5′-3′ single-stranded DNA-specific exonuclease that was 
reported to be associated with illegitimate recombination 
[19]. To the best of our knowledge, there have been no 
reports that have examined mutations in the recJ gene or 
the role of this protein in Enterococcus spp. Further stud-
ies are therefore are needed to reveal the association, if 
any, between mutations in recJ and the development of 
DNSE.
Conclusions
In conclusion, we isolated a strain of vancomycin-sus-
ceptible, DAP non-susceptible E. faecium, which sur-
vived exposure to high-dose (10  mg  kg−1  day−1) DAP 
for treatment of E. faecium endocarditis. Whole-genome 
sequencing revealed mutations within the mutL and recJ 
genes of the DNSE strain, while in  vitro analyses dem-
onstrated that the DNSE strain exhibited higher rates of 
spontaneous mutation than did the parental strain. Our 
findings demonstrate that careful monitoring is necessary 
to avoid the emergence of DAP non-susceptible isolates 
of E. faecium, in spite of high-dose therapy, and par-
ticularly in cases of long-term DAP use or in immuno-
compromised patients such as those with hematological 
malignancy. Our study did not include the demonstration 
of the relationship of these DNA repair genes mutations 
with phenotypic changes, and we were unable to deter-
mine the exact mechanism of resistance. Further investi-
gation is necessary to elucidate the mechanism by which 
E. faecium acquires DAP resistance, as well as the contri-
bution of mutations in the DNA mismatch repair genes 
mutL and recJ to this process.
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